Articles

Biodegradable thermal packaging is revolutionizing pharmaceutical shipping by delivering reliable temperature control with significantly reduced environmental impact. As demand for sustainable cold-chain logistics grows, these materials offer strong insulation, reduced waste and improved supply-chain efficiency. The industry still faces challenges like cost, scalability and regulatory alignment, but innovation is accelerating. Advances in biodegradable foams, compostable coolant packs and smart eco-sensors point to a future where sustainable, high-performance packaging becomes the global standard for transporting sensitive medications.
Biodegradable thermal packaging is revolutionizing the standards for transporting temperature-sensitive pharmaceuticals through global supply chains. As comp…

As digital mental health tools grow more sophisticated, UK regulators are drawing clearer lines between wellbeing support and medical devices. New MHRA guidance focuses on intended purpose and functional impact, helping developers understand when AI driven tools require medical device compliance.
Across the world, demand for mental-health support is exploding. Anxiety, depression, and sleep disorders are no longer fringe concerns but are headline issues, with health services struggling to keep up with the demand. Long waiting lists, staff shortages, and patchy access mean millions of people are left to cope alone. Into this gap has rushed a wave of Digital Mental Health Technologies (DMHTs) such as apps, platforms, and AI-powered tools promising fast, private, and tailored support. The gl…

No major new announcements were reported regarding outbound licensing deals, overseas approvals, or commercialization milestones for Chinese innovative drugs. Industry attention remains on the strong momentum throughout 2025, with first-half outbound licensing transactions exceeding $60 billion, dominated by ADCs, bispecific antibodies, and other advanced modalities, including multiple record-breaking deals (e.g., SanSheng Pharma's $6.05 billion bispecific antibody agreement with Pfizer). Stock index adjustments have increased weightings for biopharma sectors, reflecting policy support for new productive forces, though no immediate specific outbound events emerged. Companies like China Biopharmaceutical anticipate landing significant licensing deals by year-end, reinforcing internationalization as a key growth driver.

Descubra las principales terapias antitumorales, los tipos de cáncer más relevantes y las estrategias modernas de tratamiento, con una visión de cómo las innovaciones en curso están dando forma al futuro de la oncología.
 El cáncer sigue siendo uno de los problemas de salud más importantes a nivel mundial, afectando a millones de personas cada año. Y su tratamiento a menudo conlleva dolor, sufrimiento e incertidumbre. Hoy, sin embargo, la oncología está siendo rápidamente transformada por la innovación tecnológica: desde inhibidores específicos hasta terapias celulares, y desde degradadores emergentes hasta anticuerpos biespecíficos. El campo de la oncología mundial está entrando en una “década dorada de terapias innovadoras”. Estos avances no sólo prolongan la vida de los pacientes, s…

European pharma is undergoing regulatory reform aimed at speeding access and balancing innovation with affordability. While new rules and incentives are emerging, major companies often view investment prospects outside Europe as more attractive, even as regional policy shifts seek to strengthen competitiveness.
Major regulatory overhaul in the EUThe European Union’s lawmakers have agreed a provisional pharma package to modernise medicine rules, speed up patient access, and boost competitiveness across the bloc. New provisions include defined periods of data and market protection for novel drugs and tools to improve supply security and antibiotic development. Some industry groups argue the measures still lag behind US incentives, potentially limiting Europe’s investment attractiveness. Reute…

2026 looks set to be a landmark year for therapeutics as late‑stage programs convert into global regulatory filings and commercial launches. Advances span neurology, immunology, cardiology, oncology, metabolic disease and rare genetic disorders, driven by targeted biologics, next‑generation cell and gene therapies, and improved small‑molecule and peptide agents. Expect broader access via biosimilars and formulation innovations (e.g., subcutaneous and oral versions), faster patient impact from accelerated pathways, and shifting treatment paradigms as pivotal trial successes translate into regionally staggered approvals and rapid market rollout.
Drug / Asset Developer Indication Expected region(s) Concise regulatory status Pivotal trial Oveporexton Takeda Narcolepsy (orexin‑2 agonist)…

2025 marked a historic breakout for Chinese innovative drugs: total out-licensing deals exceeded $100 billion, with three record-shattering transactions—Sanofi-Pfizer ($1.25B upfront), Hengrui-GSK ($12.5B), and Innovent-Takeda ($11.4B). 66 novel drugs were approved as R&D spending and clinical trials surged. Lower costs (30-40% of US levels) and strength in ADC, GLP-1, and oncology assets drove global giants to aggressively partner with Chinese biotechs. The Hang Seng Innovative Drug Index rose 60% from June, reflecting renewed confidence. DengYueMed views 2025 as China’s true “going-global” inflection point.
As we wrap up 2025, the pharmaceutical landscape in China has undergone a seismic shift, one that positions the country not just as a manufacturing powerhouse but as a global innovator…

A drug launch is the coordinated process of making a new therapy available after regulatory approval. It includes market access, medical education, commercial strategy, sales engagement, marketing, supply chain, safety monitoring, analytics, and patient support. Successful launches drive adoption and long term product impact.
A drug launch is one of the most defining events in the pharma and biotech lifecycle. It marks the moment a therapy moves from years of research and clinical testing into real world availability for patients. Launch success can determine whether a company grows, stalls, or even survives. Below is a clear,…

In 2026, NHS CIOs will shift focus from flashy AI tools to strategic, outcome-driven platforms that improve clinical care, streamline operations, and deliver measurable value.
AI continued to dominate the conversation in 2025, but in 2026, healthcare CIOs are shifting gears. After a year of rapid adoption and high expectations surrounding artificial intelligence, 2026 is shaping up to be the year CIOs apply a more strategic lens. Not to slow progress, but to steer it in a smarter direction. One that aligns with the NHS 10-Year Plan and delivers on integrated care ambitions. In 2025, we saw the rise of AI copilots across almost every platform imaginable as the world raced to embrace assistance-on-demand. But whil…

Independent survey exposes significant gaps in quality systems, supply chain oversight and data integration as EU GMP regulations tighten
OXFORD, UK, December 9, 2025 — Nearly one in four European pharmaceutical companies remains vulnerable to regulatory risks due to inadequate quality systems, according to new research from NSF, a leading global public health and safety organization.The independent study conducted by Opinium surveyed 100 senior regulatory and quality leaders across Europe and the UK. It found that 23% of companies operate with only basic compliance-level quality systems, exposing them to significant regulatory and operational risks as regulatory authority expectations increase.“European life sciences organizations are facing profound structural changes, from stricter regul…

The field of oncology is advancing rapidly with innovative anti-tumor therapeutics that enhance efficacy and reduce side effects through technologies like liposomes and albumin-bound formulations.
In the rapidly evolving field of oncology, the development of advanced anti-tumor therapeutics continues to offer new hope for patients battling various forms of cancer. As global healthcare systems grapple with rising cancer incidences, pharmaceutical innovations—particularly in targeted drug delivery systems like liposomes and albumin-bound formulations—are playing a pivotal role in improving treatment efficacy while minimizing side effects. This article explores key advancements in anti-tumor products, highlighting how these formulations are transforming cancer care and the importance of effici…

Digital first healthcare is transforming clinical trial engagement with AI, analytics, and personalised digital tools. Real time insights, adaptive education, and proactive communication strengthen retention, improve data quality, and build trust, helping sponsors deliver more efficient and patient centered trials.
The rise of digital-first healthcare is reshaping how clinical trial sponsors view patient engagement. Once focused primarily on regulatory compliance and data collection, patient engagement is now expanding to include features that improve the patient experience via communication and continuous support throughout the clinical journey. According to McKinsey, most healthcare consumers expect their interactions to be personalized and digitally enabled, implying that trial participa…

A collection of comments from life science and healthcare leaders regarding the UK's Autumn Budget.
The UK BioIndustry Association (BIA) welcomes key measures in today’s Autumn Budget that support the growth of life science and biotech scale-ups, while flagging concerns over rising costs for laboratory space. Commenting on the Chancellor's Autumn Budget 2025, Jane Wall, Managing Director of the UK BioIndustry Association (BIA), said: "BIA has long argued that outdated limits on venture investment tax incentives and employee share options are holding back the scale-up of life science companies, so we are delighted that the Chancellor has chosen to extend these today. Ahead of the Budget, the CEOs of 200 of our member companies wrote to the Chancellor calling for these changes, so we are pl…

As the biologics landscape accelerates toward increasingly complex, hybrid modalities, Syngene is positioning itself at the nexus of chemistry and biology. We sat down with Peter Bains, MD & CEO of Syngene International at CPHI Frankfurt, to discuss how the company is responding to this shift — from recent investments in peptide synthesis and ADC bioconjugation to the expanding expectations of CDMO partners, the growing role of automation, and India’s emergence as a global scientific force. In our conversation, Bains offers a clear view of how integrated capabilities, digital maturity, and cross-functional collaboration are shaping the next era of drug development.
 1) Syngene has made two significant investments recently — in peptide synthesis and ADC bioconjugation. What do these mov…

Vendor neutral MSP models give life sciences organisations a scalable and transparent way to manage post market surveillance. By combining real world data expertise, merit based staffing and continuous quality oversight, they deliver faster insights, stronger compliance and a more agile response to global regulatory demands.
In a complex regulatory environment, post-market surveillance is a continuous process that demands precision, adaptability and scale. As life sciences organizations increasingly rely on real-world data to understand the long-term safety and performance of medical products, the workforce behind these efforts must be equally dynamic. This is where the vendor-neutral MSP post-market surveillance model comes into play. Challenges in Traditional Device Monitoring Traditiona…

Pharmacovigilance (PV) is an essential component in the patient safety system to find, evaluate and prevent adverse effects for medicinal products. As the life sciences sector continues to mature beyond national boundaries, pharmaceutical and biotech companies are given a strategic option — to choose global pharmacovigilance consulting services, or local PV partners.
Global vs Local Pharmacovigilance Consulting Partner Pharmacovigilance (PV) is an essential component in the patient safety system to find, evaluate and prevent adverse effects for medicinal products. As the life sciences sector continues to mature beyond national boundaries, pharmaceutical and biotech companies are given a strategic option — to choose global pharmacovigilance consulting services, or local PV partners. Each ap…

Recombinant Human Albumin Injection (Oryza Sativa), or OsrHSA, is a plant-based therapy for hypoalbuminemia (≤30 g/L) in cirrhosis patients, developed by Wuhan Healthgen Biotechnology. Produced from rice grains, it provides a safe alternative to plasma-derived albumin, free from pathogen risks and supply issues. Approved by China's NMPA on July 18, 2025, phase III trials showed non-inferior efficacy in increasing albumin levels and managing ascites. The NCT06355479 study confirmed its safety in decompensated cirrhosis. Hong Kong wholesalers like DengYuePharma specialize in exporting such rare drugs globally, boosting access. This advances sustainable biotech in liver care.
Hypoalbuminemia, characterized by serum albumin levels ≤30 g/L, is a common complication in patients with cirrhosis, of…